Peptides, longevity science, and the wellness strategies that help you age well.
A new randomized trial in The Lancet suggests semaglutide may meaningfully reduce heavy drinking and cravings in adults with alcohol use disorder and obesity, hinting at a deeper link between metabolic and reward biology.
Read more →GLP-1 therapies are often framed around weight loss and glucose control, but emerging research suggests they may also influence chronic inflammation across multiple organ systems.
Read more →GLP-1 medications reduce appetite, but they cannot outrun alcohol, poor sleep, and inflammatory meals. Here is how I coach my patients to reset after a long weekend.
Read more →Metformin has long been a cornerstone of PCOS care, but many women need more. Here's what a 2025 review reveals about semaglutide, metformin, and combination therapy for weight and metabolic outcomes.
Read more →The latest ACSM Position Stand confirms what I see in clinic every week: muscle is one of the most important tissues women can protect as hormones begin to shift.
Read more →Peptides are one of the fastest-growing tools in longevity medicine, but the real safety question isn't what you're taking. It's where it came from.
Read more →Midlife weight gain isn't a willpower problem. It's a physiology shift, and the newest incretin therapies are pointing us toward the metabolic pathways that change most during perimenopause.
Read more →Peptides are everywhere in the longevity conversation right now - and a lot of it is hype. Here's a clear, clinical look at what they actually are.
Read more →